DOCSLIB.ORG

The Annual 2018 Journal for Breeders and Producers of Plant Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Annual 2018 Journal for Breeders and Producers of Plant Material The Annual 2018 Journal for breeders and producers of plant material Prophyta 2018.indd 1 17-04-18 09:28 inspections • Quality inspections • Import inspections • Plant Passport Naktuinbouw safeguards • Quality-plus systems • NAL / Naktuinbouw-Elite and promotes the quality, testing and research identity and health of • Health and quality testing horticultural propagating • Seed analysis • Diagnostic testing material • DNA tests • Disease resistance 1 testing registration, listing and plant breeders’ rights • DUS Testing for Plant Breeders’ Rights for agricultural and horticultural crops • Description of varieties education • Identity investigation • Regular workshops and training courses • In company workshops and training courses Naktuinbouw +31 (0)71 332 6262 [email protected] www.naktuinbouw.com prophyta annual 2017 Prophyta 2018.indd 2 17-04-18 09:28 Prophyta – The Annual 2018 A publication of the Prophyta Foundation in co-operation The Annual 2018 with Blue Bird Publishers Journal for breeders and producers of plant material editorial advisory board Theo Ruys, John van Ruiten and Jan Timmerman publisher/chief editor Monique Krinkels contributing editors Anke van den Hurk, Geert-Jan de Klerk, Radha Ranganathan, Marlies Reus, Fabiola Rivera, John van Ruiten, Jan Velema, Christiaan Weijts 4 In Short 22 the idealists cover photograph Dr. Gianpaolo Grassi 5 Editorial Sowing relief in Africa sub editor Mireille McNutt 3 6 world seed congress 2018 25 seed drying graphic design Marcel Bakker, De Ontwerperij Innovative atmosphere offers Energy efficiency becomes more printed by Global Printing important address Blue Bird Publishers fertile ground for seed industry vof, Jan Kostelijklaan 16 27 half a century of seed enhancement 1981 cg Velsen-Zuid Innovation never stops the Netherlands phone +31 (0)255 521 852 28 sow to grow fax +31 (0)847 510 694 Let’s play plant breeder [email protected] www.bluebirdpublishers.com prophyta foundation [email protected] www.prophyta.org © 2018 All rights reserved. No portion of contents may be reproduced in any form without written permission from the publisher. The publisher and authors declare that they have 8 australia compiled this publication The ongoing debate on the carefully and to the best of their knowledge. However, history of agriculture no warranty or representation 12 digital sequence information (dsi) not is made to the accuracy or the very first hybrid plant completeness of information the solution 30 contained in the articles. The Trapped by biodiversity Oxheart cabbage (just) beat maize publisher and authors assume no liability whatsoever for any legislation 33 25-27 september 2018 damage resulting from the Seed meets Technology celebrates use of this publication or its contents. five-year anniversary 34 ista 2018 annual meeting in japan Flourishing Asian market inviting 36 an overview Mineral nutrition in plant tissue culture 16 seed health testing The Annual 2018 Journal for breeders and producers of plant material What you need to know when using a PCR assay On the cover: At the Italian 20 medicinally cannabis research institute crea-ci Cannabidiol opens new market Cannabis sativa L. varieties were developed the medical for breeders world was waiting for Prophyta 2018.indd 3 17-04-18 09:28 In Short Get Prophyta ments; all aimed at providing be sent to a p.o. box, so please you with information that really provide a valid street address for free matters. (either company address or Besides ‘Prophyta – The private address). Annual’, we also publish How to subscribe for ‘Prophyta – Focus on Europe’. your free copy? Earlier editions of ‘Prophyta The latter edition is dedicated In order to guarantee that – The Annual’ and ‘Prophyta – to the interests of participants Focus on Europe you receive ‘Prophyta – The Focus on Europe’ can be down- Journal for breeders and producers of plant material of the esa Annual Meeting and Annual’ and/or ‘Prophyta – loaded from www.prophyta. will be published annually on Focus on Europe’ at the correct org. Prophyta is represented at the occasion of this congress. address, please email your the isf Congress and the esa 4 Hence, this publication will be name, organisation/company, Annual Meeting by Monique distributed exclusively to pro- sales. In-depth interviews with postal address and function to Krinkels, chief editor. You are fessionals in the seed industry, leading international profes- [email protected]. welcome to call at her desk working in the areas of breed- sionals, broad articles about Please note that due to postal and receive an extra copy and ing, production, marketing and current and future develop- restrictions, Prophyta cannot subscribe. Climate change threatens doomsday vault The Svalbard International Seed Vault on the Norwegian island of Spitsber- gen, which was founded 10 years ago, will receive a new entrance. It should provide better protection for the approximately 1 million seeds from 234 countries that are now stored there. At the end of 2016, water was discovered near the entrance. Because of the exceptionally high temperatures and rain at the end of that year, water had entered the 100-metre long tunnel to the seed vault. The moisture did not get any further because it was frozen, but scientists started to worry. It has now been decided to build a new watertight entrance. Norway will spend 100 million Norwegian Crowns (€ 10.4 million) to upgrade the doomsday seed vault. The work is expected to last until May next year. The seed vault was constructed in an has the capacity to store 4.5 million crop war or global warming kills certain crops, abandoned Arctic coal mine at a depth of varieties. The aim is to store and safeguard governments will be able to request seeds 120 meters in a mountain in the vicinity of the world’s crops and plants against global from the vault to restart their agricultural Lonyearbyen, the capital of Spitsbergen. It natural or man-made disasters. If nuclear industries. Record in Nanopore Sequencing This year, KeyGene research- run 48 such flow cells, large- for KeyGene’s partners Rijk KeyGene with a single Prome- ers generated 76 gigabases scale de novo whole genome Zwaan, Enza Zaden, Limagrain thion flow cell thus represents of dna sequence of a lettuce sequencing will soon be Vegetable Seeds and Takii & approximately 30-fold genome (Lactuca sativa) genome with a feasible. KeyGene expects that Co, which use the genome coverage. The N50 reads single Oxford Nanopore Tech- Promethion’s long reads and sequence to support the lengths were 29 kb with a fair nologies (ont) Promethion low costs per base will disrupt development of new varieties. amount of reads longer than flow cell. This is a new record the current sequencing field, Lettuce has a complex genome 100 kb. With these very long in the plant genome sequenc- accelerating crop innovation. of approximately 2.7 gigabase dna sequences, the assembly ing area for long reads. As the The nanopore sequencing of the pairs (Gbp). The output of of complex genomes becomes Promethion has the capacity to lettuce genome was completed 76 gigabases generated by much easier. prophyta annual 2018 Prophyta 2018.indd 4 17-04-18 09:28 In Short Editorial Short circuit in communication Workshop on seed identification Nowadays, people suffer from an information overload. Apart 5 from the daily newspaper, television and radio, they also receive This autumn, Naktuin- identification is not a prerequi- e-mails, e-newsletters, e-magazines, read Facebook, Instagram bouw (Netherlands Inspec- site to attending the workshop. and Twitter, and search the Internet for the latest developments in tion Service for Horticulture) will again organise a Seed Content of the scientific, economic and business-related topics. The drawback Identification Workshop for workshop of the rapid advances made in information and communication international participants. The Over the three days, technology. At the same time, the paradoxical situation is that, workshop will take place from participants are given lectures, although there is an abundance of information available, it is often 1-3 October 2018 in Roelofar- excursions and plenty of practi- difficult to obtain useful, relevant information when it is needed. endsveen, the Netherlands. The cal assignments in which they No wonder that managers sometimes feel overwhelmed and aim is to improve identification have to identify seeds under the of seeds found as impurities in microscope themselves. A first productivity falters, as reading and sifting takes too much time of seed samples. The participants major step in seed identification the individual. learn how to identify seeds and is the recognition of the plant Nevertheless, the seed industry wants the general public to learn fruits from the seventeen most family to which a particular more about seeds and plant breeding. There is a need to open important wild plant families seed/fruit belongs, making it the ‘black box’ in the food chain, as many people hardly know occurring in European arable possible to consult reference landscapes. These plant fami- collections efficiently and seed what happens to food before it is displayed in the supermarket. lies are responsible for frequent atlases for a final identification. And even if they are aware that there are farmers involved in impurities. In this workshop, a selection of food manufacturing, the processes of plant breeding and seed The workshop is specifically families has been introduced production remain hidden from sight. ‘Unknown is unloved’, as developed for seed analysts that represent the majority of a Dutch proverb goes, and it makes the sector an easy target for and those in industry who are the seeds from the ista univer- unfounded criticism. involved in seed purity analysis sal list of plant species. and/or seed identification. More information available at: Seed organisations have recognised the need and have taken Specific knowledge of seed www.naktuinbouw.eu action. isf and esa are active on Twitter and Facebook, asta offers, among others, blogs by plant breeders.
Load more

Recommended publications
  • SUU Alm.Del Bilag 444: Itamar Grotto
    Sundheds- og Ældreudvalget 2017-18 SUU Alm.del Bilag 444 Offentligt MINISTRY OF HEALTH Medical Grade Cannabis - The Israeli Roadmap to Medicalization Prof. Itamar Grotto Associate Director General, Israeli Ministry of Health Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Medical use of Cannabis in ancient times • 5000 years ago in Egyptian tombs • 2700 years ago in India • 2000 years ago in China for the treatment of pain Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH International - Single Convention on Narcotic Drugs 1961 The Cannabis plant is subject to additional measures of control Israel - The Dangerous Drug Ordinance [New Version] - 1973 The Cannabis plant and its products are defined as narcotic substances They are not registered as medicinal products Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Government of Israel Resolutions Government Resolution 3609 (7.8.2011) • Establishes the obligation of the Ministry of Health to serve as “Government Agency” for Cannabis • The multi-ministerial Stirring Committee • The Israeli Medical Cannabis Agency (IMCA) is established Government Resolution 1050 (15.12.2013) • Improving efficiency of prescription, indication inspection, appointing of Physicians and accessibility to service. • Search for feasibility of export • Regulating research. Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH Government Resolution 1587 (26.6.2016) - Cannabis for medical purpose and research The “Medicalization” of Cannabis Medical Grade Cannabis - MINISTRY The Israeli Roadmap to Medicalization OF HEALTH The Vision of The Israeli Medical Cannabis Agency (IMCA) To support the use of Cannabis for medical purposes exclusively, while preventing misuse and keeping public safety.
    [Show full text]
  • Israeli Cannabis Company 'Together' Announced an Agreement with a Canadian Company to Sell 50 Tons of Cannabis Inflorescences Or 5 Tons of Cannabis Oil
    Israeli cannabis company 'Together' announced an agreement with a Canadian company to sell 50 tons of cannabis inflorescences or 5 tons of cannabis oil The company estimates the potential annual revenue from the deal at hundreds of millions of shekels. "This agreement joins other existing sales agreements in Canada and German totaling 30 tons. These agreements ensure the creation of revenue and cash flow that are not dependent on export approval from the State of Israel, and which will derive from the sale of medical cannabis and its products from areas that we will set up in countries outside of Israel that have the relevant export agreements", said Globus Pharma founding partner Nissim Bracha Israel, Ashkelon, April 11 2018 – 'Together' (TASE: TGTR) announced that its activity company 'Globus Pharma', which specializes in the medical cannabis sector and operates as a subsidiary of 'Together', has signed a Memorandum of Understanding (MoU) to sell medical cannabis or oil to a Canadian company with a license to grow, produce and import medical cannabis to Canada. Under the terms of the agreement, the Canadian company will buy from Globus 50 tons of dried inflorescences of cannabis each year or five tons of medical cannabis oil (the equivalent amount to 50 tons of inflorescences) as part of the terms of the law in Canada and in Israel. In addition, the two companies will collaborate in the field of R&D and promoting technologies in the medical cannabis sector. As of the date of signing the agreement, the parties estimate that sales revenue will amount to between US$3.17 and US$4.7 per gram of inflorescence.
    [Show full text]
  • Roots Sustainable Agricultural Technologies Ltd Arbn 619 754 540 Notice of Annual General Meeting
    ROOTS SUSTAINABLE AGRICULTURAL TECHNOLOGIES LTD ARBN 619 754 540 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 2:30 pm (WST) DATE: Thursday, 16 September 2021 PLACE: Suite 2, Level 1 1 Altona Street WEST PERTH WA 6005 The business of the Meeting affects your shareholding and your vote is important. This Notice of Meeting should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) and to section 182 of the Companies Law and the regulations promulgated thereunder, that the persons eligible to vote at the Meeting are those who are registered Shareholders at 5:00pm (WST) on 14 September 2021. BUSINESS OF THE MEETING AGENDA 1. FINANCIAL STATEMENT AND REPORTS Review and discussion of the audited annual financial report of the Company for the financial year ended 31 December 2020 together with the declaration of the directors, the director’s report and the auditor’s report. 2. RESOLUTION 1 – APPOINTMENT OF AUDITORS To consider and, if thought fit, to pass, with or without amendment, the following resolution: “RESOLVED, that BDO – Ziv Haft be, and hereby is, appointed as the independent auditors of the Company for the year 2021 and for an additional period until the next annual general meeting.” The affirmative vote of at least a majority of the voting power represented at the Meeting, in person or by proxy and voting thereon, is required to adopt this Resolution.
    [Show full text]
  • 2017 Global Drug Survey
    Prepared by the GDS Core Research Team Dr Adam Winstock, Dr Monica Barratt, Dr Jason Ferris & Dr Larissa Maier Global overview and highlights N > 115,000 Global Drug Survey GDS2017 © Not to be reproduced without authors permission Hi everyone On behalf of the GDS Core Research Team and everyone of our amazing international network partners and supportive media organisations we’d like to share our headline report deck. I know it won’t have everything that everyone wants but we are hopeful it will give people an idea of how the world of drugs is changing and highlight some of the key things that we think people can better engage with to keep themselves and those they care for safe. Once we cleaned the data from 150,000 people we chose to use data from just under 120,000 people this year for these reports. We have data reports addressing 18 different areas for over 25 countries. We can only share a fraction of what we have here on the site. However, we are very open to sharing the other findings we have and would ask researchers and public health groups to contact us so we can discuss funding and collaboration. We have almost completed designing GDS2018 so that we can start piloting early and give countries where we have not yet found friends to reach out to us. We particularly want to hear from people in Japan, Eastern Europe, Africa and the Middle East. Dr Adam R Winstock Founder and CEO Global Drug Survey Consultant Psychiatrist and Addiction Medicine Specialist Global Drug Survey GDS2017 © Not to be reproduced without authors permission We think this will be interesting.
    [Show full text]
  • Access to Medicinal Cannabis: Meeting Patient Needs
    Access to medicinal cannabis: meeting patient needs All-Party Parliamentary Group for Drug Policy Reform Inquiry Report “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.” Constitution of the World Health Organisation drawn up in 1946 in conformity with the Charter of the United Nations Foreword For six years, the All-Party Parliamentary Group for Drug Policy Reform has worked for an end to the “war on drugs” driven by the USA and supported by the UN. In our “Guidance on Interpreting the UN Drugs Conventions”, we called for three major changes: 1. evidence-based drugs policy; 2. policy that genuinely promotes the health and welfare of mankind driven by human rights and public health values; 3. flexibility for Member States to develop drug policy within the UN Conventions based on our four “Guidance” principles. We have had meetings with the President of the UN Economic and Social Council (ECOSOC); the Executive Director of the UN Office on Drugs and Crime (UNODC); and the Deputy Secretary General of the UN. We have organised international meetings of Ministers and senior officials in Westminster and spoken at international meetings in New York, Brussels and Cartagena, Colombia. At the UN General Assembly Special Session (UNGASS) held in April 2016, we witnessed both the USA and the UN leadership reject a moralistic and prohibitionist approach to the global drug problem. Instead, the UN and US leaders called for all our proposed changes to global drugs policy.
    [Show full text]
  • Israel Takes the Next Steps Towards Legalizing Recreational Cannabis
    Article Cannabis Law July 2020 Israel Takes the Next Steps Towards Legalizing Recreational Cannabis By Andrew J. Wilder and Jonathan Mahoney Israel is considered one of the global leaders in medical cannabis research and innovation. In 1964, Professor Raphael Mechoulam of the Hebrew University of Jerusalem was the first person to isolate and identify THC, the psychoactive chemical component in cannabis that causes a high. While limited use of cannabis for medicinal purposes has been permitted in Israel since the early 1990s, it took 53 years from Professor Mechoulam’s breakthrough before the Public Security Ministry partially decriminalized cannabis in 2017, setting fines and treatment for initial offenders instead of criminal procedures. Earlier this year, after much bureaucratic delay, the export of medical cannabis was finally approved and is estimated to generate hundreds of millions of dollars in revenue annually. Now, three years since its decriminalization, Israel is on the verge of legalizing cannabis for recreational use. On June 9th, 2020, just one week after the State of Israel police minister declared that enforcement of the existing laws related to cannabis possession and use would be relaxed, two of Israel’s largest political parties issued a joint statement, agreeing to move forward with cannabis law reform. In the joint statement provided by Likud Prime Minister Benjamin Netanyahu and Blue and White’s Defense Minister Benny Gantz, they advised that reform to existing legislation was required with the aim to “resolve the issue of decriminalization and legalization” of cannabis in Israel. In addition to legalizing recreational cannabis, the proposed reforms will also make it easier for patients to gain access to treatment and for producers to become licensed to grow and sell medical cannabis.
    [Show full text]
  • FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer
    FORM 5 QUARTERLY LISTING STATEMENT Name of Listed Issuer: MPX International Corporation (“MPXI” or the “Issuer”). Trading Symbol: MPXI This Quarterly Listing Statement must be posted on or before the day on which the Issuer’s unaudited condensed interim financial statements are to be filed under the Securities Act, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer’s first, second and third fiscal quarters. This statement is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website. Currency Unless otherwise stated, all dollar amounts are expressed in Canadian dollars. General Instructions (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer. (b) The term “Issuer” includes the Listed Issuer and any of its subsidiaries. (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.
    [Show full text]
  • Bol-Pharma-Prospectus.Pdf
    A copy of this preliminary prospectus has been filed with the securities regulatory authorities in each of the provinces and territories of Canada but has not yet become final for the purpose of the sale of securities. Information contained in this preliminary prospectus may not be complete and may have to be amended. The securities may not be sold until a receipt for the prospectus is obtained from the securities regulatory authorities. No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus constitutes a public offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ‘‘U.S. Securities Act’’), or the securities laws of any state of the United States and may not be offered or sold, directly or indirectly, in the United States or in any other jurisdiction where the offer or sale of such securities is not permitted, except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws, or securities laws of any other relevant jurisdiction. This prospectus does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction where the offer, sale or solicitation of an offer to buy any of these securities is not permitted. See ‘‘Plan of Distribution’’.
    [Show full text]
  • Review of Contemporary Knowledge of the Treatment Effects Of
    Review of Contemporary Knowledge of the Treatment Effects of Cannabis and Related Products, and Its Outlook Tomáš Zábranský 1, 4), Lumír Hanuš 1, 2, 4), Richard Rokyta 1, 3, 4) 1) International Cannabis and Cannabinoids Institute, Prague 2) Hebrew University in Jerusalem, Israel 3) Department of Normal, Pathological and Clinical Physiology, 3rd Faculty of Medicine, Charles University in Prague 4) Společnost pro léčbu konopím a kanabinoidy a jejich výzkum, z.s. [Czech Society for Medical Treatment with Cannabis and Cannabinoids and Their Research] CONTENTS CONTENTS .............................................................................................................................................................. 1 ABSTRACT............................................................................................................................................................... 3 KEY WORDS ............................................................................................................................................................ 3 RECOMMENDED CITATION: .................................................................................................................................... 4 INTRODUCTION ...................................................................................................................................................... 4 METHODS ..............................................................................................................................................................
    [Show full text]
  • Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations
    molecules Article Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations Alberto Ramella 1, Gabriella Roda 2, Radmila Pavlovic 3,*, Michele Dei Cas 4 , Eleonora Casagni 2, Giacomo Mosconi 3, Francisco Cecati 5, Paola Minghetti 2 and Carlo Grizzetti 6 1 Farmacia Dott.ri Giuliana e Alberto Ramella–SAS, Via A. Diaz 1, 21021 Angera (VA), Italy; [email protected] 2 Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milan, Italy; [email protected] (G.R.); [email protected] (E.C.); [email protected] (P.M.) 3 Department of Health, Animal Science and Food Safety, University of Milan, 20133 Milan, Italy; [email protected] 4 Department of Health Sciences, Università degli Studi di Milano, Via A.di Rudinì 8, 20142 Milan, Italy; [email protected] 5 INTEQUI-CONICET, Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis, Almirante Brown 1455, San Luis CP 5700, Argentina; [email protected] 6 S.S.D. Cure Palliative e Terapia del Dolore, Ospedale di Circolo–Fondazione Macchi, ASST Sette Laghi, Viale L. Borri 57, 21100 Varese, Italy; [email protected] * Correspondence: [email protected] Academic Editor: Maria Carla Marcotullio Received: 2 June 2020; Accepted: 29 June 2020; Published: 30 June 2020 Abstract: The feasibility of the use of two lipid sources and their impact on the cannabinoid profile, terpene fingerprint, and degradation products in medical cannabis oil preparations during 3 months of refrigerated storage time were investigated. LCHRMS-Orbitrap® and HS-SPME coupled to GC-MS for the investigation of targeted and untargeted cannabinoids, terpenes, and lipid degradation products in Bedrocan® and Bediol® macerated oils were used as analytical approaches.
    [Show full text]
  • Patterns of Use of Medical Cannabis Among Israeli
    Vol. 49 No. 2 February 2015 Journal of Pain and Symptom Management 223 Original Article Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience Barliz Waissengrin, MD, Damien Urban, MD, Yasmin Leshem, MD, Meital Garty, BA, and Ido Wolf, MD Institute of Oncology (B.W., M.G., I.W.), Tel Aviv Sourasky Medical Center, Tel Aviv; Institute of Oncology (D.U., Y.L.), Chaim Sheba Medical Center, Ramat Gan; and Sackler Faculty of Medicine (I.W.), Tel Aviv University, Tel Aviv, Israel Abstract Context. The use of the cannabis plant (Cannabis sativa L.) for the palliative treatment of cancer patients has been legalized in multiple jurisdictions including Israel. Yet, not much is currently known regarding the efficacy and patterns of use of cannabis in this setting. Objectives. To analyze the indications for the administration of cannabis among adult Israeli cancer patients and evaluate its efficacy. Methods. Efficacy and patterns of use of cannabis were evaluated using physician-completed application forms, medical files, and a detailed questionnaire in adult cancer patients treated at a single institution. Results. Of approximately 17,000 cancer patients seen, 279 (<1.7%) received a permit for cannabis from an authorized institutional oncologist. The median age of cannabis users was 60 years (range 19e93 years), 160 (57%) were female, and 234 (84%) had metastatic disease. Of 151 (54%) patients alive at six months, 70 (46%) renewed their cannabis permit. Renewal was more common among younger patients and those with metastatic disease. Of 113 patients alive and using cannabis at one month, 69 (61%) responded to the detailed questionnaire.
    [Show full text]
  • Annual Information Form
    CRONOS GROUP INC. ANNUAL INFORMATION FORM For the year ended December 31, 2018 DATED: March 25, 2019 TABLE OF CONTENTS GENERAL MATTERS ............................................................................................................................................... 3 FORWARD LOOKING INFORMATION ............................................................................................................... 3 CORPORATE STRUCTURE .................................................................................................................................... 6 GENERAL DEVELOPMENT OF THE BUSINESS ............................................................................................... 7 DESCRIPTION OF THE BUSINESS ..................................................................................................................... 13 ALTRIA STRATEGIC INVESTMENT ................................................................................................................. 39 RISK FACTORS ....................................................................................................................................................... 43 DIVIDENDS AND DISTRIBUTIONS ..................................................................................................................... 76 CAPITAL STRUCTURE .......................................................................................................................................... 76 MARKET FOR SECURITIES ................................................................................................................................
    [Show full text]